Autor:	S. Famularo, M. Donadon, F. Cipriani, F. Giuliante, A. Ferrero, S. Molfino, R. Dalla Valle, M. Chiarelli, M. Maestri, E. Jovine, G.L. Grazi, A. Ruzzenente, R. Memeo, M. Crespi, A. Antonucci, D.P. Bernasconi, F. Romano, G. Griseri, L. Aldrighetti, G. Torzilli, F. Trevisani, on behalf of ITA.LI.CA. Group and HE.RC.O.LE.S. Group
Rok vydání:	2021
Předmět:	Oncology Sorafenib medicine.medical_specialty Hepatology business.industry Internal medicine Hepatocellular carcinoma Gastroenterology medicine business medicine.disease medicine.drug
Zdroj:	Digestive and Liver Disease. 53:S41
ISSN:	1590-8658
DOI:	10.1016/j.dld.2020.12.098
Databáze:	OpenAIRE
Externí odkaz:	https://explore.openaire.eu/search/publication?articleId=doi_________::be22a96ef448e897038d2a1a57714da3 https://doi.org/10.1016/j.dld.2020.12.098 Zobrazit plný text záznamu Full Text from ScienceDirect